bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S2 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Table.S2: Gene sets enrichment for down regulated (Log2 fold change < 0 & adj.p.value < 0.1) genes in Man2a1-knockout B16F10 cells. "MAGeCKFlute" R package was used to perform the analysis.
Supplementary Figure Legend from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Supplementary Figure Legend
Figure S8 from Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Authors: Shi Sailing , Gu Shengqing , Han Tong , Zhang Wubing , Huang Lei , Li Ziyi , Pan Deng , Fu Jingxin , Ge Jun , Brown Myles , Zhang Peng , Jiang Peng , Wucherpfennig Kai W. , Liu X. Shirley
Published: April 2023

Sup.Fig.8: The effect of Man2a1 knockout on the immune cell infiltration.
Figure S2 from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Authors: Chawla Sant P. , Goel Sanjay , Chow Warren , Braiteh Fadi , Singh Arun S. , Olson Juneko E. Grilley , Osada Atsushi , Bobe Iulian , Riedel Richard F.
Published: April 2023

Figure S2. shows mean Change in EORTC QLQ-C30 Score from Baseline.
Supplementary Tables from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Authors: Norsworthy Kelly J. , Mulkey Flora , Scott Emma C. , Ward Ashley F. , Przepiorka Donna , Charlab Rosane , Dorff Sarah E. , Deisseroth Albert , Kazandjian Dickran , Sridhara Rajeshwari , Beaver Julia A. , Farrell Ann T. , de Claro R. Angelo , Pazdur Richard
Published: April 2023

Supplementary Tables
Supplementary Figure 3 from Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Authors: Norsworthy Kelly J. , Mulkey Flora , Scott Emma C. , Ward Ashley F. , Przepiorka Donna , Charlab Rosane , Dorff Sarah E. , Deisseroth Albert , Kazandjian Dickran , Sridhara Rajeshwari , Beaver Julia A. , Farrell Ann T. , de Claro R. Angelo , Pazdur Richard
Published: April 2023

Supplementary Figure 3. Blood count trajectory for patients with or without DS.
Supplementary Tables from Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Authors: Martini Jean-François , Plimack Elizabeth R. , Choueiri Toni K. , McDermott David F. , Puzanov Igor , Fishman Mayer N. , Cho Daniel C. , Vaishampayan Ulka , Rosbrook Bradley , Fernandez Kathrine C. , Tarazi Jamal C. , George Saby , Atkins Michael B.
Published: April 2023

Supplementary Tables
Supplementary fig 3 from A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Authors: Wu Annie A. , Bever Katherine M. , Ho Won Jin , Fertig Elana J. , Niu Nan , Zheng Lei , Parkinson Rose M. , Durham Jennifer N. , Onners Beth , Ferguson Anna K. , Wilt Cara , Ko Andrew H. , Wang-Gillam Andrea , Laheru Daniel A. , Anders Robert A. , Thompson Elizabeth D. , Sugar Elizabeth A. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary fig 3 Swimmer's plot demonstrating individual outcomes for Arm A and B patients.
Supplementary Data from Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models
Authors: Bordini Jessica , Morisi Federica , Elia Angela Rita , Santambrogio Paolo , Pagani Alessia , Cucchiara Vito , Ghia Paolo , Bellone Matteo , Briganti Alberto , Camaschella Clara , Campanella Alessandro
Published: April 2023

Supplementary materials and methods and Supplementary Figures S1-S12
Supplementary fig 2 from A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Authors: Wu Annie A. , Bever Katherine M. , Ho Won Jin , Fertig Elana J. , Niu Nan , Zheng Lei , Parkinson Rose M. , Durham Jennifer N. , Onners Beth , Ferguson Anna K. , Wilt Cara , Ko Andrew H. , Wang-Gillam Andrea , Laheru Daniel A. , Anders Robert A. , Thompson Elizabeth D. , Sugar Elizabeth A. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary fig 2 Schematic overview of 10-color Multiplex IHC and Image visualization.
Supplementary Figure 6 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 6: TIL expansion outcome greatly differs between tumor samples from the same patient
Supplementary Figure 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 1: TIL expansion is reproducible
Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Authors: Smyth Lillian M. , Tamura Kenji , Oliveira Mafalda , Ciruelos Eva M. , Mayer Ingrid A. , Sablin Marie-Paule , Biganzoli Laura , Ambrose Helen J. , Ashton Jack , Barnicle Alan , Cashell Des D. , Corcoran Claire , de Bruin Elza C. , Foxley Andrew , Hauser Joana , Lindemann Justin P.O. , Maudsley Rhiannon , McEwen Robert , Moschetta Michele , Pass Martin , Rowlands Vicky , Schiavon Gaia , Banerji Udai , Scaltriti Maurizio , Taylor Barry S. , Chandarlapaty Sarat , Baselga José , Hyman David M.
Published: April 2023

Supplementary tables
Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Authors: Smyth Lillian M. , Tamura Kenji , Oliveira Mafalda , Ciruelos Eva M. , Mayer Ingrid A. , Sablin Marie-Paule , Biganzoli Laura , Ambrose Helen J. , Ashton Jack , Barnicle Alan , Cashell Des D. , Corcoran Claire , de Bruin Elza C. , Foxley Andrew , Hauser Joana , Lindemann Justin P.O. , Maudsley Rhiannon , McEwen Robert , Moschetta Michele , Pass Martin , Rowlands Vicky , Schiavon Gaia , Banerji Udai , Scaltriti Maurizio , Taylor Barry S. , Chandarlapaty Sarat , Baselga José , Hyman David M.
Published: April 2023

Supplementary Figure 3. AKT1E17K Allele Frequency (AF) Distribution and Median AF for patients with available ctDNA NGS data
Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

B cell gating
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

Supplementary tables
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

Protocol
Supplementary fig 4 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Supplementary fig 4 Baseline p-ERK score in Tumor Tissue Correlated to RAS/RAF Mutation Status
Supplementary fig 1 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Supplementary fig 1 Flowchart for trial design
Supplementary Data from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Table showing next generation sequencing of tumor samples
Supplementary Table 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Authors: Gray Katherine D. , McCloskey Jaclyn E. , Vedvyas Yogindra , Kalloo Olivia R. , Eshaky Steve El , Yang Yanping , Shevlin Enda , Zaman Marjan , Ullmann Timothy M. , Liang Heng , Stefanova Dessislava , Christos Paul J. , Scognamiglio Theresa , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M. , Min Irene M.
Published: April 2023

Summary of donor T cells used for CAR T cell generation and response to anti-PD1 antibody treatment in vitro and in vivo.
Supplementary Figure 1 from PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
Authors: Gray Katherine D. , McCloskey Jaclyn E. , Vedvyas Yogindra , Kalloo Olivia R. , Eshaky Steve El , Yang Yanping , Shevlin Enda , Zaman Marjan , Ullmann Timothy M. , Liang Heng , Stefanova Dessislava , Christos Paul J. , Scognamiglio Theresa , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M. , Min Irene M.
Published: April 2023

Expression of ICAM1 and PD-L1 in anaplastic thyroid tumor cell lines.
Supplementary Data from HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome
Authors: Rosenbaum Evan , Seier Kenneth , Bandlamudi Chaitanya , Dickson Mark , Gounder Mrinal , Keohan Mary L. , Chi Ping , Kelly Ciara , Movva Sujana , Nacev Benjamin , Simeone Noemi , Donoghue Mark , Slotkin Emily K. , Qin Li-Xuan , Antonescu Cristina R. , Tap William D. , D'Angelo Sandra P.
Published: April 2023

Supplementary Tables
supplementary figures from Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Authors: Chong Wan Qin , Lim Chwee Ming , Sinha Arvind Kumar , Tan Chee Seng , Chan Gloria Hui Jia , Huang Yiqing , Kumarakulasinghe Nesaretnam Barr , Sundar Raghav , Jeyasekharan Anand D. , Loh Woei Shyang , Tay Joshua K. , Yadav Kritika , Wang Lingzhi , Wong Andrea L. , Kong Li Ren , Soo Ross Andrew , Lau Jieying Amelia , Soon Yu Yang , Goh Robby Miguel , Ho Francis Cho Hao , Chong Siew Meng , Lee Soo Chin , Loh Kwok Seng , Tai Bee Choo , Lim Yaw Chyn , Goh Boon Cher
Published: April 2023

Figure S1- Study schema Figure S2 - Example of complete metabolic response after 3 cycles of induction therapy in a representative Arm C patient treated with bevacizumab at 7.5mg/kg in combination with cisplatin and gemcitabine. Figure S3- Relapse free survival (RFS) in months by study arms of patients with locally advanced disease who underwent concurrent chemoradiation after induction chemotherapy. Figure S4 - Relapse free survival in months by metabolic response to induction therapy. Figure S5 - (A) Spaghetti Plot of EBV viral load at baseline (BL), C2D1 and C3D1; (B)Circulating VEGF levels in plasma samples collected at BL, C1D1, C2D1 and end of induction therapy, EOT. Figure 6a- Figure S6 - Induction of mature blood vessel in the NPC tumour microenvironment 7 days following initiation of sunitinib and bevacizumab exposure. Figure S6b - Quantification of blood vessel densities Figure S7- Immune cell infiltration in the NPC tumour microenvironment 7 days following initiation of sunitinib or bevacizumab exposure
Supplemental Methods and Figure Legends from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Supplemental Methods and Figure Legends
Supplemental Figure SF-14 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Compared to Treatment Naïve Tumors (Group B and 2 untreated patients), IC treated Tumors (Group A) Demonstrate Increased Amounts of Growth Factor Expression, Oncogene and Immune Gene Expression, but Decreased Amounts of Melanoma Related Genes
Supplementary Data_Clean from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

contains methods.
Supplemental Figure SF-12 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Some Cluster of Differentiation Expression Prognosticates Favorable Survival in Group A and Group B
Figure S6 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S6
Figure S4 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S4
Supplemental Figure SF-05 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

The Majority of Immunologic Gene Signatures Significantly Predict RFS and OS in Group A, but not in Group B.
Supplemental Figure SF-03 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Hu14.18-IL2 Treatment Improves Direct Positive Correlations between Myeloid and Lymphoid Cells as indicated by ssGSEA Signatures
Supplemental Figure SF-02 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Gene Signatures Prognosticating Survival after IC Treatment
Supplementary Methods from Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Authors: Pesch Andrea M. , Hirsh Nicole H. , Chandler Benjamin C. , Michmerhuizen Anna R. , Ritter Cassandra L. , Androsiglio Marlie P. , Wilder-Romans Kari , Liu Meilan , Gersch Christina L. , Larios José M. , Pierce Lori J. , Rae James M. , Speers Corey W.
Published: April 2023

Supplementary Materials and Methods Section
Figure S3 from CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Authors: Kane Joshua R. , Zhao Junfei , Tsujiuchi Takashi , Laffleur Brice , Arrieta Víctor A. , Mahajan Aayushi , Rao Ganesh , Mela Angeliki , Dmello Crismita , Chen Li , Zhang Daniel Y. , González-Buendia Edgar , Lee-Chang Catalina , Xiao Ting , Rothschild Gerson , Basu Uttiya , Horbinski Craig , Lesniak Maciej S. , Heimberger Amy B. , Rabadan Raul , Canoll Peter , Sonabend Adam M.
Published: April 2023

Activators of MAPK signaling correlate to macrophage markers in human GBM patients. (A) Correlation of mRNA expression analysis of 161 GBM patients in TCGA library between ITGAM (CD11b) and MAPK13 (n=161). (B) Correlation between AIF1 (Iba1) and RRAS (n=161). (C) Correlation between AIF1 and MAPK13 (n=161). (D) Correlation between AIF1 and MAP3K8 (n=161). r and p values by Pearson correlation coefficient. Points represent individual GBM patients.
Supplementary Table S1 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Steps of Cox regression analyses to final models.
Supplemental Figure 2 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Authors: Santa-Maria Cesar A. , Coughlin Janelle W. , Sharma Dipali , Armanios Mary , Blackford Amanda L. , Schreyer Colleen , Dalcin Arlene , Carpenter Ashley , Jerome Gerald J. , Armstrong Deborah K. , Chaudhry Madhu , Cohen Gary I. , Connolly Roisin M. , Fetting John , Miller Robert S. , Smith Karen L. , Snyder Claire , Wolfe Andrew , Wolff Antonio C. , Huang Chiung-Yu , Appel Lawrence J. , Stearns Vered
Published: April 2023

Exploratory analysis comparing weight loss across various clinical subgroups.
Supplemental Figure 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Authors: Santa-Maria Cesar A. , Coughlin Janelle W. , Sharma Dipali , Armanios Mary , Blackford Amanda L. , Schreyer Colleen , Dalcin Arlene , Carpenter Ashley , Jerome Gerald J. , Armstrong Deborah K. , Chaudhry Madhu , Cohen Gary I. , Connolly Roisin M. , Fetting John , Miller Robert S. , Smith Karen L. , Snyder Claire , Wolfe Andrew , Wolff Antonio C. , Huang Chiung-Yu , Appel Lawrence J. , Stearns Vered
Published: April 2023

Change in waist circumference from baseline to six-months in patients assigned to POWER-remote and self-directed arms.
Supplementary Tables S1-S4 from Autoantibody Landscape in Patients with Advanced Prostate Cancer
Authors: Chen William S. , Haynes Winston A. , Waitz Rebecca , Kamath Kathy , Vega-Crespo Agustin , Shrestha Raunak , Zhang Minlu , Foye Adam , Baselga Carretero Ignacio , Perez Garcilazo Ivan , Zhang Meng , Zhao Shuang G. , Sjöström Martin , Quigley David A. , Chou Jonathan , Beer Tomasz M. , Rettig Matthew , Gleave Martin , Evans Christopher P. , Lara Primo , Chi Kim N. , Reiter Robert E. , Alumkal Joshi J. , Ashworth Alan , Aggarwal Rahul , Small Eric J. , Daugherty Patrick S. , Ribas Antoni , Oh David Y. , Shon John C. , Feng Felix Y.
Published: April 2023

Supplementary Tables S1-S4
Figure S1 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Glisson Bonnie S. , Leidner Rom S. , Ferris Robert L. , Powderly John , Rizvi Naiyer A. , Keam Bhumsuk , Schneider Reva , Goel Sanjay , Ohr James P. , Burton Jennifer , Zheng Yanan , Eck Steven , Gribbin Matthew , Streicher Katie , Townsley Danielle M. , Patel Sandip Pravin
Published: April 2023

Figure S1: Best change from baseline in tumor burden
Supplementary Text from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Supplementary Text
Supplementary Fig3 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

reproducibility graphs
Supplementary Table 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Supplementary Table 2
Supplementary Figure 5 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Figure 5: Histopathology of the HuCCT-1 xenograft tumors from control group and groups treated with gemcitabine and gemcitabine in combination with tocilizumab.
Supplementary Figure 7 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Explorative analyses of overall survival according to standardized KELIM terciles (upper vs intermediate + lower) and completeness of interval debulking surgery. Med.: Median; IDS: interval debulking surgery; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Table S5 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

Summary of significantly altered gene expression with BRAF inhibitor treatment
Table S2 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

Kinase Array densitometry quantification
Figures S1-11 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

Supplementary Figures 1-11. 1. CSF cytology of leptomeningeal patient cohort. 2. Additional clinical timelines of leptomeningeal patient cohort 3. Patient MRIs 4. RNAseq Workflow 5. Differential responses to BRAFi treatment in CSF 6. RNAseq shows CSF from Patient 4 to elicit transcriptional modulation of melanoma cell response to BRAF inhibition 7. CSF from LMM patients elicits transcriptional changes in melanoma cells 8. CSF protects melanoma cells from BRAF inhibitor therapy 9. CSF activates AKT in WM164 10. No-LMM CSF does not induce expression of TGFbeta or activation of AKT 11. ELISA assay showing the levels of TGFβ1 in CSF specimens from extrordi- nary responder (Patient 1) and non-responders.
Supplementary Data from A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors
Authors: Tolaney Sara M. , Do Khanh T. , Eder Joseph P. , LoRusso Patricia M. , Weekes Colin D. , Chandarlapaty Sarat , Chang Ching-Wei , Chen Shang-Chiung , Nazzal Denise , Schuth Eva , Brunstein Flavia , Carrasco-Triguero Montserrat , Darbonne Walter C. , Giltnane Jennifer M. , Flanagan William M. , Commerford S. Renee , Ungewickell Alexander , Shapiro Geoffrey I. , Modi Shanu
Published: April 2023

Tables S1 to S9 Figures S1 to S6
Supplementary Data from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Zeidan Amer M. , Ridinger Maya , Lin Tara L. , Becker Pamela S. , Schiller Gary J. , Patel Prapti A. , Spira Alexander I. , Tsai Michaela L. , Samuëlsz Errin , Silberman Sandra L. , Erlander Mark , Wang Eunice S.
Published: April 2023

Supplementary Tables and Figure
Supplementary Data from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Authors: Hewitt Susannah L. , Bailey Dyane , Zielinski John , Apte Ameya , Musenge Faith , Karp Russell , Burke Shannon , Garcon Fabien , Mishra Ankita , Gurumurthy Sushma , Watkins Amanda , Arnold Kristen , Moynihan James , Clancy-Thompson Eleanor , Mulgrew Kathy , Adjei Grace , Deschler Katharina , Potz Darren , Moody Gordon , Leinster David A. , Novick Steve , Sulikowski Michal , Bagnall Chris , Martin Philip , Lapointe Jean-Martin , Si Han , Morehouse Chris , Sedic Maja , Wilkinson Robert W. , Herbst Ronald , Frederick Joshua P. , Luheshi Nadia
Published: April 2023

Supplementary Methods
Supplemental Table 3 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Device performance
Supplementary Methods from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Authors: Hammer Stefanie , Hagemann Urs B. , Zitzmann-Kolbe Sabine , Larsen Aasmund , Ellingsen Christine , Geraudie Solene , Grant Derek , Indrevoll Baard , Smeets Roger , von Ahsen Oliver , Kristian Alexander , Lejeune Pascale , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S. , Mumberg Dominik
Published: April 2023

Supplementary Methods
Supplementary Figures from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Authors: Hammer Stefanie , Hagemann Urs B. , Zitzmann-Kolbe Sabine , Larsen Aasmund , Ellingsen Christine , Geraudie Solene , Grant Derek , Indrevoll Baard , Smeets Roger , von Ahsen Oliver , Kristian Alexander , Lejeune Pascale , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S. , Mumberg Dominik
Published: April 2023

Figures and Figure Legends for Supplementary Figures 1, 2, 3, 4 and 5
Supplemental Table 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

All adverse events reported on the study
Supplemental Figure 5 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Microinjection of olaratumab does not inhibit PDGFRÎ±, ERK, or S6 phosphorylation.
Supplementary Data from T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Obradovic Aleksandar Z. , Dallos Matthew C. , Zahurak Marianna L. , Partin Alan W. , Schaeffer Edward M. , Ross Ashley E. , Allaf Mohamad E. , Nirschl Thomas R. , Liu David , Chapman Carolyn G. , O'Neal Tanya , Cao Haiyi , Durham Jennifer N. , Guner Gunes , Baena-Del Valle Javier A. , Ertunc Onur , De Marzo Angelo M. , Antonarakis Emmanuel S. , Drake Charles G.
Published: April 2023

Supplementary Figure Captions
FigureS2 from T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Obradovic Aleksandar Z. , Dallos Matthew C. , Zahurak Marianna L. , Partin Alan W. , Schaeffer Edward M. , Ross Ashley E. , Allaf Mohamad E. , Nirschl Thomas R. , Liu David , Chapman Carolyn G. , O'Neal Tanya , Cao Haiyi , Durham Jennifer N. , Guner Gunes , Baena-Del Valle Javier A. , Ertunc Onur , De Marzo Angelo M. , Antonarakis Emmanuel S. , Drake Charles G.
Published: April 2023

Figure S2
FigureS1 from T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Obradovic Aleksandar Z. , Dallos Matthew C. , Zahurak Marianna L. , Partin Alan W. , Schaeffer Edward M. , Ross Ashley E. , Allaf Mohamad E. , Nirschl Thomas R. , Liu David , Chapman Carolyn G. , O'Neal Tanya , Cao Haiyi , Durham Jennifer N. , Guner Gunes , Baena-Del Valle Javier A. , Ertunc Onur , De Marzo Angelo M. , Antonarakis Emmanuel S. , Drake Charles G.
Published: April 2023

Figure S1
Supplemental Figure 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Clinical Trial Design
Table S3 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Table 3: Summary statistics for cellularity in 4-chemokinehi and 4-chemokinelo groups in primary resections
Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

In patients treated with vorinostat and everolimus, there was a longer median progression-free survival in patients with normal LDH compared to patients with high LDH (5.8 months, 4.4 - 7.2 vs. 1.6 months, 95% CI 1.3-1.9; P < 0.001).
Supplementary Figure 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Dose modifications: vorinostat and everolimus
Table S2 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Lesion response data
Table S2 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Hazard ratios and 95% confidence intervals of the association between statin use and risk of prostate cancer subgroups defined by tumor characteristics, among men reporting high-intensity PSA screening
Table S1 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Hazard ratios and 95% confidence intervals of the association between statin use and risk of prostate cancer subgroups defined by tumor characteristics
Figure S3 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Flow Parameters and Strategy
Supplementary Tables from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

Further information on antibodies, differentially expressed genes, clinical characteristics, survival analysis, mutations, and methylation.
Supplementary Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
Authors: Friedman Jay , Moore Ellen C. , Zolkind Paul , Robbins Yvette , Clavijo Paul E. , Sun Lilian , Greene Sarah , Morisada Megan V. , Mydlarz Wojciech K. , Schmitt Nicole , Hodge James W. , Schreiber Hans , Van Waes Carter , Uppaluri Ravindra , Allen Clint
Published: April 2023

Supplemental data not critical for the main conclusions of the work but important for critical review of the data.
Figure S5 from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

Differentially expressed genes between the T cell infiltration groups and boxplots of gene expression.
Supplementary Tables S1-S3 from Methylomic Landscapes of Ovarian Cancer Precursor Lesions
Authors: Pisanic Thomas R. , Wang Yeh , Sun Hanru , Considine Michael , Li Lihong , Wang Tza-Huei , Wang Tian-Li , Shih Ie-Ming
Published: April 2023

Supplementary Tables S1-S3
Supplementary Figures S1-S5 from Methylomic Landscapes of Ovarian Cancer Precursor Lesions
Authors: Pisanic Thomas R. , Wang Yeh , Sun Hanru , Considine Michael , Li Lihong , Wang Tza-Huei , Wang Tian-Li , Shih Ie-Ming
Published: April 2023

Supplementary Figures S1-S5
Supplementary Tables from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary tables
Supplementary Methods from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

Supplemental material and methods
Figure S5 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

ADI-PEG20 efficacy in an extended panel of ovarian cancer cell lines. Cells were treated with 0.63 µg/mL ADI-PEG20. First row represents ASS1 expressing cell lines, whereas the rest of the cells are ASS1 deficient, therefore sensitive to ADI-PEG20 treatment. OVCAR3: HGSC cell line; JHOC 9, OVTOKO: CCOC cell lines. BIN67, SCCOHT1: SCCOHT cell lines; OVISE and ES2 represent atypical CCOC/ENOC based on molecular characterizations; TOV112D: de-differentiated ovarian cancer cell line. Error bars represent standard error of mean.
Supplementary Figure 4 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure